NEGVAC in talks with offshore manufacturers for import of Covid jabs: Govt

In a written reply to a question in the Rajya Sabha, MoS for Health Bharati Pravin Pawar said as on July 16, a total of 2.61 lakh doses of the Sputnik V vaccine have been administered in the country

Coronavirus vaccine, Covid-19 vaccine, Covid vaccine
No doses of the Moderna and Pfizer vaccines have so far been received under the US donation programme, the minister said in response to another question
Press Trust of India New Delhi
2 min read Last Updated : Jul 20 2021 | 8:53 PM IST
The National Empowered Group on Vaccine Administration against Covid-19 is in regular talks with offshore manufacturers, including Moderna, for importing Covid vaccines, but the exact number of doses to be imported and their manner of allocation have not been finalised yet, the government informed Parliament on Tuesday.
 
In a written reply to a question in the Rajya Sabha, Minister of State for Health Bharati Pravin Pawar said as on July 16, a total of 2.61 lakh doses of the Sputnik V vaccine have been administered in the country.
 
On how the government plans the allocation of the Moderna vaccine and the number of doses to be procured, the minister said, "The NEGVAC (National Empowered Group on Vaccine Administration against Covid-19) is in regular dialogue with offshore Covid-19 vaccine manufacturers including Moderna for import of Covid vaccines. However, the exact number of doses to be imported and their manner of allocation have not been finalised yet."

On the current status of the arrival of the Pfizer and Moderna vaccines in India, Pawar said the Covid-19 vaccine manufactured by Moderna has been approved for restricted use in emergency situation by the Drugs Controller general of India (DCGI), while the one manufactured by Pfizer is not yet approved by the national drugs regulator.
 
No doses of the Moderna and Pfizer vaccines have so far been received under the US donation programme, the minister said in response to another question, adding that the NEGVAC is deliberating with offshore manufacturers, including Moderna and Pfizer, for the procurement of vaccines. 
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineVaccinationVaccine

Next Story